PubMed:24700979 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PubMed/sourceid/24700979","sourcedb":"PubMed","sourceid":"24700979","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/24700979","text":"A comparison of two visual inspection methods for cervical cancer screening among HIV-infected women in Kenya.\nOBJECTIVE: To determine the optimal strategy for cervical cancer screening in women with human immunodeficiency virus (HIV) infection by comparing two strategies: visual inspection of the cervix with acetic acid (VIA) and VIA followed immediately by visual inspection with Lugol's iodine (VIA/VILI) in women with a positive VIA result.\nMETHODS: Data from a cervical cancer screening programme embedded in two HIV clinic sites in western Kenya were evaluated. Women at a central site underwent VIA, while women at a peripheral site underwent VIA/VILI. All women positive for cervical intraepithelial neoplasia grade 2 or worse (CIN 2+) on VIA and/or VILI had a confirmatory colposcopy, with a biopsy if necessary. Overall test positivity, positive predictive value (PPV) and the CIN 2+ detection rate were calculated for the two screening methods, with biopsy being the gold standard.\nFINDINGS: Between October 2007 and October 2010, 2338 women were screened with VIA and 1124 with VIA/VILI. In the VIA group, 26.4% of the women tested positive for CIN 2+; in the VIA/VILI group, 21.7% tested positive (P \u003c 0.01). Histologically confirmed CIN 2+ was detected in 8.9% and 7.8% (P = 0.27) of women in the VIA and VIA/VILI groups, respectively. The PPV of VIA for biopsy-confirmed CIN 2+ in a single round of screening was 35.2%, compared with 38.2% for VIA/VILI (P = 0.41).\nCONCLUSION: The absence of any differences between VIA and VIA/VILI in detection rates or PPV for CIN 2+ suggests that VIA, an easy testing procedure, can be used alone as a cervical cancer screening strategy in low-income settings.","tracks":[{"project":"Allie","denotations":[{"id":"SS1_24700979_2_0","span":{"begin":200,"end":228},"obj":"expanded"},{"id":"SS2_24700979_2_0","span":{"begin":230,"end":233},"obj":"abbr"},{"id":"SS1_24700979_2_1","span":{"begin":274,"end":322},"obj":"expanded"},{"id":"SS2_24700979_2_1","span":{"begin":324,"end":327},"obj":"abbr"},{"id":"SS1_24700979_7_0","span":{"begin":849,"end":874},"obj":"expanded"},{"id":"SS2_24700979_7_0","span":{"begin":876,"end":879},"obj":"abbr"}],"relations":[{"id":"AE1_24700979_2_0","pred":"abbreviatedTo","subj":"SS1_24700979_2_0","obj":"SS2_24700979_2_0"},{"id":"AE1_24700979_2_1","pred":"abbreviatedTo","subj":"SS1_24700979_2_1","obj":"SS2_24700979_2_1"},{"id":"AE1_24700979_7_0","pred":"abbreviatedTo","subj":"SS1_24700979_7_0","obj":"SS2_24700979_7_0"}],"attributes":[{"subj":"SS1_24700979_2_0","pred":"source","obj":"Allie"},{"subj":"SS2_24700979_2_0","pred":"source","obj":"Allie"},{"subj":"SS1_24700979_2_1","pred":"source","obj":"Allie"},{"subj":"SS2_24700979_2_1","pred":"source","obj":"Allie"},{"subj":"SS1_24700979_7_0","pred":"source","obj":"Allie"},{"subj":"SS2_24700979_7_0","pred":"source","obj":"Allie"}]},{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":160,"end":175},"obj":"HP_0030079"},{"id":"T2","span":{"begin":169,"end":175},"obj":"HP_0002664"},{"id":"T3","span":{"begin":206,"end":222},"obj":"HP_0002721"}],"attributes":[{"subj":"T1","pred":"source","obj":"PubmedHPO"},{"subj":"T2","pred":"source","obj":"PubmedHPO"},{"subj":"T3","pred":"source","obj":"PubmedHPO"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"Allie","color":"#ec93a1","default":true},{"id":"PubmedHPO","color":"#93bbec"}]}]}}